Rejuvenated T cells attack old tumors

OncoImmunology

Volumn 2, Issue 2, 2013, Pages

  Galluzzi, Lorenzo ^a,b,c   Lugli, Enrico ^d  

^a UNIVERSITÉ PARIS DESCARTES   (France)

^b CENTRE DE RECHERCHE DES CORDELIERS   (France)

^c INSTITUT GUSTAVE ROUSSY   (France)

^d HUMANITAS CLINICAL AND RESEARCH CENTER   (Italy)

Author keywords

Adoptive cell transfer; Central memory T cells; Effector memory T cells; Stem cell memory T cells; T cell receptor; Tumor associated antigens

Indexed keywords

ANTINEOPLASTIC AGENT; CD27 ANTIGEN; CD28 ANTIGEN; CD45RA ANTIGEN; GAMMA INTERFERON; GLYCOGEN SYNTHASE KINASE 3BETA; INTERLEUKIN 15; INTERLEUKIN 7; MELAN A;

ADOPTIVE TRANSFER; ANTIGEN EXPRESSION; ANTIGEN FUNCTION; CELL COMPARTMENTALIZATION; CELL EXPANSION; DOSE RESPONSE; DRUG MEGADOSE; EDITORIAL; HUMAN; LYMPHOCYTE DIFFERENTIATION; LYMPHOCYTE FUNCTION; LYMPHOCYTE PROLIFERATION; PRIORITY JOURNAL; PROTEIN FUNCTION; SIGNAL TRANSDUCTION; T LYMPHOCYTE SUBPOPULATION; TUMOR IMMUNITY; TUMOR IMMUNOLOGY;

EID: 84886943709     PISSN: 21624011     EISSN: 2162402X     Source Type: Journal    
DOI: 10.4161/onci.24103     Document Type: Editorial

References (17)

1. Galluzzi L, Vacchelli E, Eggermont A, Fridman WH, Galon J, Sautès-Fridman C, et al. Trial Watch: Adoptive cell transfer immunotherapy. Oncoimmunology 2012; 1:306-15; PMID:22737606; http://dx.doi. org/10.4161/onci.19549.
2. Wen FT, Thisted RA, Rowley DA, Schreiber H. A systematic analysis of experimental immunotherapies on tumors differing in size and duration of growth. Oncoimmunology 2012; 1:172-8; PMID:22720238; http://dx.doi.org/10.4161/onci.1.2.18311.
3. Vacchelli E, Galluzzi L, Eggermont A, Galon J, Tartour E, Zitvogel L, et al. Trial Watch: Immunostimulatory cytokines. Oncoimmunology 2012; 1:493-506; PMID:22754768; http://dx.doi.org/10.4161/onci.20459.
4. Mahnke YD, Devevre E, Baumgaertner P, Matter M, Rufer N, Romero P, et al. Human melanomaspecific CD8(+) T-cells from metastases are capable of antigen-specific degranulation and cytolysis directly ex vivo. Oncoimmunology 2012; 1:467-530; PMID:22754765; http://dx.doi.org/10.4161/onci.19856.
5. Gattinoni L, Klebanoff CA, Restifo NP. Paths to stemness: building the ultimate antitumour T cell. Nat Rev Cancer 2012; 12:671-84; PMID:22996603; http://dx.doi.org/10.1038/nrc3322.
6. Davila ML, Brentjens R, Wang X, Rivière I, Sadelain M. How do CARs work?: Early insights from recent clinical studies targeting CD19. Oncoimmunology 2012; 1:1577-83; PMID:23264903; http://dx.doi.org/10.4161/onci.22524.
7. Perfetto SP, Chattopadhyay PK, Roederer M. Seventeen-colour flow cytometry: unravelling the immune system. Nat Rev Immunol 2004; 4:648-55; PMID:15286731; http://dx.doi.org/10.1038/nri1416.
8. Lugli E, Dominguez MH, Gattinoni L, Chattopadhyay PK, Bolton DL, Song K, et al. Superior T memory stem cell persistence supports long-lived T cell memory. J Clin Invest 2013; PMID:23281401; http://dx.doi.org/10.1172/JCI66327.
9. Gattinoni L, Lugli E, Ji Y, Pos Z, Paulos CM, Quigley MF, et al. A human memory T cell subset with stem cell-like properties. Nat Med 2011; 17:1290-7; PMID:21926977; http://dx.doi.org/10.1038/nm.2446.
10. Somerville RP, Dudley ME. Bioreactors get personal. Oncoimmunology 2012; 1:1435-7; PMID:23243620; http://dx.doi.org/10.4161/onci.21206.
11. Cieri N, Camisa B, Cocchiarella F, Forcato M, Oliveira G, Provasi E, et al. IL-7 and IL-15 instruct the generation of human memory stem T cells from naive precursors. Blood 2013; 121:573-84; PMID:23160470; http://dx.doi.org/10.1182/blood-2012-05-431718.
12. Nishimura T, Kaneko S, Kawana-Tachikawa A, Tajima Y, Goto H, Zhu D, et al. Generation of rejuvenated antigen-specific T cells by reprogramming to pluripotency and redifferentiation. Cell Stem Cell 2013; 12:114-26; PMID:23290140; http://dx.doi.org/10.1016/j.stem.2012.11.002.
13. Vizcardo R, Masuda K, Yamada D, Ikawa T, Shimizu K, Fujii S, et al. Regeneration of human tumor antigen-specific T cells from iPSCs derived from mature CD8(+) T cells. Cell Stem Cell 2013; 12:31-6; PMID:23290135; http://dx.doi.org/10.1016/j.stem.2012.12.006.
14. Vacchelli E, Martins I, Eggermont A, Fridman WH, Galon J, Sautès-Fridman C, et al. Trial watch: Peptide vaccines in cancer therapy. Oncoimmunology 2012; 1:1557-76; PMID:23264902; http://dx.doi.org/10.4161/onci.22428.
15. Haymaker C, Wu R, Bernatchez C, Radvanyi L. PD-1 and BTLA and CD8(+) T-cell "exhaustion" in cancer: "Exercising" an alternative viewpoint. Oncoimmunology 2012; 1:735-8; PMID:22934265; http://dx.doi.org/10.4161/onci.20823.
16. Zitvogel L, Kroemer G. Targeting PD-1/PD-L1 interactions for cancer immunotherapy. Oncoimmunology 2012; 1:1223-5; PMID:23243584; http://dx.doi.org/10.4161/onci.21335.
17. Song DG, Powell DJ. Pro-survival signaling via CD27 costimulation drives effective CAR T-cell therapy. Oncoimmunology 2012; 1:547-9; PMID:22754782; http://dx.doi.org/10.4161/onci.19458.